Management of patients with community-acquired pneumonia in a primary care hospital: A critical evaluation

Respiratory Medicine

Volumn 94, Issue 6, 2000, Pages 556-563

  Ewig, S ^a   Seifert, K ^b   Kleinfeld, T ^b   Goke N ^a,b   Schafer H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Dreifaltigkeits Krankenhaus Wesseling   (Germany)

Author keywords

Antimicrobial treatment; Hospitalization; Outcome; Pneumonia; Severity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; IMIPENEM; MACROLIDE; METRONIDAZOLE; PENICILLIN G; QUINOLONE; UREIDOPENICILLIN DERIVATIVE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; COMMUNICABLE DISEASE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; FEMALE; HEALTH CARE QUALITY; HOSPITAL CARE; HOSPITALIZATION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; PATIENT CARE; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE;

EID: 0033899482     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.1999.0775     Document Type: Article

References (25)

1. Community-acquired pneumonia
2. Community-acquired pneumonia in adults: Guidelines for management
3. European study on community-acquired pneumonia (ESOCAP) Commitee. Guidelines for management of adult community-acquired lower respiratory tract infections
4. Deutsche Gesellschaft fur Pneumologie. Empfehlungen zur Therapie der ambulant erworbenen Pneumonie
5. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
6. A prediction rule to identify low-risk patients with community-acquired pneumonia
7. Aktuelle Daten zur Antibiotikaempfindlichkeit von Streptococcus pneumoniae (Pneumokokken)
8. Etiology of community-acquired pneumonia: Impact of age, comorbidity, and severity
9. Community-acquired pneumonia requiring hospitalization: 5-year prospective study
10. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
11. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, doubleblind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
12. Predicting death in patients hospitalized for community acquired pneumonia
13. Severe community acquired pneumonia. Biology, prognosis, and treatment
14. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors
15. The hospital admission decision for patients with community-acquired pneumonia
16. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases
17. Aetiology of community acquired pneumonia in Valencia, Spain: A multicentre prospective study
18. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia
19. Value of routine microbial investigation in community acquired pneumonia treated in a tertiary care center
20. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization
21. Severe community acquired pneumonia. Epidemiology and prognosis factors
22. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit